Several groups are assessing the use of cationic lipids for administration and at intervals up to 21 days thereafter. respiratory gene therapy. To date no human data are availNo adverse clinical events were seen or any statistically able regarding the safety of intra-pulmonary cationic lipid significant changes in spirometry or gas transfer. There delivery. In preparation for a trial of pulmonary delivery of were no clinically significant changes in any of the blood the CFTR gene, we have assessed the safety of nebulised parameters and no CT changes were seen. Comparisons lipid GL-67/DOPE/DMPE-PEG 5000 (GL-67A), the cationic of the cellular subpopulations (neutrophils, eosinophils, lipid formulation to be used in this study. Fifteen healthy lymphocytes and macrophages) in induced sputum volunteers were given incremental doses of GL-67A via a showed no significant alterations following administration Pari LC Jet nebuliser; three volunteers in each of five dosof the GL-67A. This study suggests that a single appliing cohorts with a week interval between cohorts. Markers cation of aerosol formulation of GL-67A does not result in of safety included clinical assessment, measurement of clinically detectable changes when given by nebulisation lung function, chest CT scan, serological testing and analyinto the lungs of normal volunteers and provides an indisis of induced sputum. Measurements were taken before cation of a lipid dose tolerated in man.
Introduction the lower airways. It also provides a potentially safer Despite modifications to the treatment regimens of environment for a phase I clinical study of gene transfer. patients with cystic fibrosis (CF) and the development of Four such studies have been reported. [4] [5] [6] [7] These trials pronew drugs such as DNase, the average life expectancy of vide evidence both for gene transfer and the production CF subjects is still only 30 years. Since the cloning of the of functional CFTR. However, the degree of correction of CF gene in 1989, 1 gene therapy has become a potential the chloride defect is generally low, with approximately therapeutic option. The CF gene codes for a protein, cys-20% of normal values achieved. The degree of correction tic fibrosis transmembrane conductance regulator required for clinical benefit is unclear although two stud-(CFTR), which functions both as a chloride channel in the ies have suggested that either correction in 5% of cells apical cell membrane of epithelial cells in the respiratory with a monolayer 8 or 5% of normal CFTR mRNA in every and intestinal tracts and in sweat glands, 2 and also regucell 9 will produce virtually complete correction of the lates other channels including those responsible for chloride defect, while correction of the Na + defect sodium transport. 3 Mutations in the CFTR gene result in appears more difficult. Thus, while gene transfer may not relative or complete absence of functional CFTR at the require a high degree of efficiency for the treatment of apical cell membrane and consequently decreased chlor-CF, it is clearly desirable to improve this if possible. To ide secretion and increased sodium uptake in these cells.
this end a number of new cationic lipids have been proHow these underlying defects relate to the pathology of duced. One of these GL-67 has shown promise in vivo in CF is poorly understood, but gene transfer offers a new animal models, achieving more efficient gene transfer therapeutic option.
than previously tested liposomes. 10 With regard to safety, Initial clinical studies for CF gene therapy have focused a dose-dependent inflammatory response was seen when on the nasal epithelium as the target site for gene translipid GL-67/DOPE was administered in vivo to the lungs fer. This region of the respiratory tract demonstrates the by direct instillation. 11 However, this was not seen when defect in chloride and sodium transport and is more it was given via a nebuliser, suggesting that the peripheral pooling of large quantities of the lipids may have been responsible for the effects seen following instillation.
In preparation for such a trial and other human studies, out intervention. In two patients the auto-antibody screen yielded consistently positive results after the adminiswe have assessed the safety of nebulised lipid GL-67A in healthy volunteers. A further aim of this study was to tration of GL-67A. One patient in dosing group 2 developed anti-cytoskeletal antibodies on day 1 after find a tolerated dose of lipid, both with regard to toxicity and duration of nebulisation, providing guidance on the administration with positive results on days 3 and 6 and a weak positive result on day 21. The second patient dose of DNA-lipid complex to be administered to the CF subjects.
(dosing group 4) developed anti-nuclear factor (nuclear pattern) on day 3 after administration and continued to have a positive test at day 21. Two further patients dem-
Results
onstrated positive antibody tests on one occasion only. One patient (group 5) had a positive rheumatoid factor Clinical result on day 1, with negative results at all other times No patient had a significant fall in forced expiratory voland one patient (group 3) had a positive anti-nuclear facume per second (FEV 1 ) during the hypotonic challenge tor (nuclear pattern) pre-treatment and on day 1 with and therefore no patients were excluded from the study.
negative results during the remainder of the study. Administration of the aerosolised GL-67A via the nebuliser was well tolerated by all subjects with no clinically Radiology apparent adverse effects. A diary card was completed by
No changes were seen in the CT scans taken after treateach subject and there were no significant symptoms at ment as compared to those prior to treatment and the any time.
chest radiographs taken at day 21 were all normal.
Blood and urine analysis
Lung function There were no clinically significant changes seen in any
There was a statistically significant decrease in both FEV 1 of the blood parameters during the trial. However, a statand forced vital capacity (FVC) at 1 h after administration istically significant decrease in urate level was seen on (Table 3) , but this was not clinically significant (4% and day 1 and a significant increase in alkaline phosphate 1.5% fall, respectively). No significant change was seen level on day 21 after administration (Table 1) . C-reactive in the gas transfer coefficient (KCOc) or gas transfer coefprotein, interleukin 1␤, and 8 and tumour necrosis factor ficient corrected for alveolar ventilation (TLCOc) (TNF) did not increase during the course of the trial.
( Table 4 ) after dosing. Small increases in interleukin 6 levels occurred in some patients in the three highest dosing groups, although this did not reach statistical significance (Table 2) . No anti-
Sputum induction
The procedure was well tolerated by all the subjects. lipid antibody was detected at any time. Urinalysis showed red cells and white cells in five out of 15 of the Results of the cytological analysis on the induced sputum sample were available in 11 out of the 15 volunteers. subjects at various times during the study (day 6 in three patients -Ͻ10 white cells and Ͻ10 red cells in each, preInsufficient sputum was expectorated in the remaining four subjects. In four out of the 11 from whom an dose and on day 3 in two patients) but this resolved with- No statistically significant changes were seen when multiple comparisons were taken into account except for (*); increased alkaline phosphate on day 21 (P = 0.006) and decreased urate on day 1 (P = 0.002). Neither of these changes were clinically significant. No statistically significant changes were seen when multiple comparisons were taken into account except (*); FEV 1 at 1 h after dose (P = 0.001), FVC at 1 h after dose (P = 0.002). These changes were not clinically significant, representing a change of Ͻ5% in both parameters.
adequate sample was obtained, it was not possible to by nebulisation to healthy volunteers and to establish guidelines for a dose which could be given to patients perform a differential count at one or other time-points due to the large numbers of squamous or lysed cells in with CF in a forthcoming trial of CFTR gene therapy. No clinically significant changes in any outcome measure the specimen. No statistical difference was seen in the total or differential cell counts performed on the induced were seen suggesting that with regard to safety, lipid formulation GL-67A is an appropriate choice for human sputum specimens obtained before and after dosing on the seven remaining subjects (three from dosing group 1, gene therapy trials.
In vivo work using cationic lipids (DC Chol/DOPE and three from group 2 and one from group 3) (Table 5) . DOTAP/DOPE) has shown no evidence of an inflammatory response or epithelial damage when complexed with
Discussion
CFTR and nebulised into mice; 5 repeated administration was well tolerated.
11 Lipids are currently in clinical use The aims of this study were to assess the safety of an aerosol formulation of the cationic lipid (GL-67A) given complexed with amphotericin as an intravenous prep-body result in the second dosing group and the positive whereas in this study we have looked at the adminisc, value corrected for patient's haemoglobin.
tration of lipid alone. Consequently, the possibility of such an increase in inflammatory markers or an immunogenic response occurring in CF subjects as a result of administration of the lipid-DNA complex cannot be However, up to half of CF subjects exhibit airway hyperresponsiveness [15] [16] [17] and nebulisation of a hypotonic prepNo statistically significant changes were seen.
aration in these people may cause bronchoconstriction. 18, 19 In order to assess the risk of this occurring, a study is currently underway to look at the effect of nebulisation of solutions of varying tonicity on CF airways. aration and inhalation of neutral lipids into the lungs of healthy volunteers has been shown to have no effect on The range of doses for this study was selected based on information from animal toxicity studies. GL-67A was spirometry and no other obvious adverse effects.
12 When administered to the nasal epithelium of man, the cationic nebulised into monkeys with no significant histological or clinical problems seen (unpublished data). The maxilipid DC-Chol/DOPE, caused no local or systemic toxic effects either when administered alone 13 or complexed mal dose safely administered to those primates was used on a weight for weight basis to estimate the maximal with CFTR cDNA. 6 However, GL-67/DOPE has demonstrable toxicity in mouse lungs that is dose-dependent. 11 dose to be administered in this study. In order to receive the highest dose, the subjects were required to use the In this study, the presence of red and white blood cells in the urine of five of the subjects occurred at different nebuliser for approximately 1 h, the maximum time which we felt would be tolerated by patients. It was also times in different subjects and showed no relation to dose. Positive auto-antibody results were seen in two necessary to allow a 1 min rest after every 50 breaths (2 ml), to achieve this nebulisation time. This adminispatients after administration of GL-67A, but both these (anti-nuclear factor and anti-cytoskeletal antibody) are tration procedure was well tolerated and forms a basis for our forthcoming CF trial. commonly found in healthy people 14 and also bore no relation to dose, with the positive anti-cytoskeletal antiThis study is the first to assess the safety of nebulis-ation of an aerosol formulation of a cationic lipid into the planned administration of lipid in order to exclude any 15.5 subject with a fall in FEV 1 of Ͼ20% as a result of the challenge. The study was approved by the Ethics Com-
The volume nebulised was calculated from the difference in mittee of the Royal Brompton Hospital and all partiweight before and after nebulisation.
cipants gave informed consent. deposition was approximately 50%, with in vivo rodent studies showing a uniform distribution with an increase at airway bifurcations. Incremental doses were given at weekly intervals by increasing the number of breaths electrolytes, liver function tests, glucose and amylase during nebulisation (Table 6 ). Three subjects were treated were performed before, and at intervals after dosing. at each dosage interval; each subject received only one Serum inflammatory markers (C-reactive protein, lipid dose. All patients stopped breathing from the nebuinterleukins 1␤, 6, 8 and TNF), serum antibody to lipid liser for 1 min after each set of 50 breaths.
Liposome administration
and an auto-antibody screen were also measured as detailed (Table 7) . Urine microscopy was also carried out Outcome measures at regular intervals and urinalysis for specific gravity, pH, acetone and bilirubin was performed. Clinical: A full medical history was taken and a physical examination performed at recruitment and at intervals Radiology: Two limited high resolution CT scans of the after dosing (Table 7) . Each subject was provided with a chest were performed on each subject, the first before, diary card to complete during the course of the trial. and the second on day 3 after dosing. A total of 12 slices were taken for each scan, six of which were taken in deep expiration. A postero-anterior chest radiograph was Blood and urine analysis: A full blood count, differential cell count and a biochemistry screen including urea and taken on day 21 after dosing.
Lung function: Spirometry was recorded on three Craig Siegel, Genzyme Corporation for their help. The study was supported by the Cystic Fibrosis Research occasions before dosing, at 1, 4 and 6 h after administration and then as detailed (Table 7) . More complete pulTrust, the Medical Research Council UK and by a Wellcome Trust Senior Clinical Fellowship (EWFWA). monary function tests including assessment of gas transfer were also performed before, and on day 3 after dosing.
